SMND-309 is a metabolite of salvianolic acid B. It also shows neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats.

SMND-309 treatment decreases the liver damage and the liver fibrosis grade. SMND-309 also reduces the elevation in the malondialdehyde level and restored the decrease in superoxide dismutase and glutathione peroxidase activities. SMND-309 treatment powerfully down-regulated the expression of connective tissue growth factor (CTGF) in serum and liver. SMND-309 (2.5-10 mg/kg; oral intragastric; once a day; for 4 weeks; male Sprague-Dawley rats) treatment ameliorates liver function and decreases the elevation of serum hyaluronic acid, laminin, procollagen type III levels and hydroxyproline content in liver tissue [1].

1065559-56-9

C18H14O8

358.3

SMND-309

DMSO:3.7 mg/mL (10.33 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years